Literature DB >> 3627719

Timing of initial probing and irrigation in congenital nasolacrimal duct obstruction.

J A Katowitz, M G Welsh.   

Abstract

A series of 427 patients with congenital dacryostenosis involving 572 eyes was seen at the Children's Hospital of Philadelphia. All patients were treated conservatively with antibiotics and massage prior to decision by the parents to request probing. Congenital dacryostenosis, as well as resolution of symptoms, were confirmed by clinical examination and use of a modified dye disappearance test. In 572 eyes, the success rate of initial probing was found to be 97% under 13 months of age. Over 13 months, however, the mean success rate was found to be 54.7%. When broken down into smaller age categories, a stepwise progression was observed from 76.4% between 13 and 18 months to 33.3% for patients probed after 24 months. In addition, the number and complexity of subsequent procedures appeared to increase along with the age at which the initial probing was performed. These data suggest that initial probing should be done prior to 13 months of age depending on the severity of symptoms and parent compliance with medical management.

Entities:  

Mesh:

Year:  1987        PMID: 3627719     DOI: 10.1016/s0161-6420(87)33392-5

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  47 in total

1.  Value of nasal endoscopy and probing in the diagnosis and management of children with congenital epiphora.

Authors:  C J MacEwen; J D Young; C W Barras; B Ram; P S White
Journal:  Br J Ophthalmol       Date:  2001-03       Impact factor: 4.638

2.  Paediatric powered endonasal dacryocystorhinostomy.

Authors:  Dania Al-Nuaimi; Clare Inkster; Christopher Lobo
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-04-26       Impact factor: 2.503

3.  Long-term results of probing guided with soft cannula in children with congenital nasolacrimal duct obstruction.

Authors:  Dilek Yuksel; Pınar Altiaylik Ozer
Journal:  Jpn J Ophthalmol       Date:  2013-11-16       Impact factor: 2.447

4.  [Increased prevalence of congenital dacryostenosis following cesarean section].

Authors:  Claudia Kuhli-Hattenbach; M Lüchtenberg; C Hofmann; T Kohnen
Journal:  Ophthalmologe       Date:  2016-08       Impact factor: 1.059

5.  Primary treatment of nasolacrimal duct obstruction with probing in children younger than 4 years.

Authors:  Michael X Repka; Danielle L Chandler; Roy W Beck; Eric R Crouch; Sean Donahue; Jonathan M Holmes; Katherine Lee; Michele Melia; Graham E Quinn; Nick A Sala; Susan Schloff; David I Silbert; David K Wallace
Journal:  Ophthalmology       Date:  2007-11-08       Impact factor: 12.079

6.  The course of epiphora after failure of silicone intubation for congenital nasolacrimal duct obstruction.

Authors:  Yanir Kassif; Uri Rehany; Michal David; Anna Popko; Shimon Rumelt
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-03-09       Impact factor: 3.117

7.  Acquired nasolacrimal duct obstruction in children.

Authors:  Kyu Mee Kay; Kyung In Woo; Jung Hoon Kim; Hae Ran Chang
Journal:  Jpn J Ophthalmol       Date:  2007-12-21       Impact factor: 2.447

8.  Paediatric endoscopic endonasal dacryocystorhinostomy in congenital nasolacrimal duct obstruction.

Authors:  Igal Leibovitch; Dinesh Selva; Angelo Tsirbas; Edward Greenrod; John Pater; Peter J Wormald
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-03-15       Impact factor: 3.117

9.  The rate of symptomatic improvement of congenital nasolacrimal duct obstruction in Japanese infants treated with conservative management during the 1st year of age.

Authors:  Hirohiko Kakizaki; Yasuhiro Takahashi; Shinsuke Kinoshita; Kunihiko Shiraki; Masayoshi Iwaki
Journal:  Clin Ophthalmol       Date:  2008-06

10.  Primary treatment of nasolacrimal duct obstruction with balloon catheter dilation in children younger than 4 years of age.

Authors:  Michael X Repka; B Michele Melia; Roy W Beck; Danielle L Chandler; Deborah R Fishman; Todd A Goldblum; Jonathan M Holmes; Bernard D Perla; Graham E Quinn; David I Silbert; David K Wallace
Journal:  J AAPOS       Date:  2008-10       Impact factor: 1.220

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.